In the discovery set with 406 cases and 592 controls, genotyping results showed that TCF21 rs2327429 and rs12190287 polymorphisms were significantly associated with the reduced risk of breast cancer (For rs2327429: C vs. T, OR = 0.83, 95%CI = 0.69-0.99, P = 0.04; CC vs. TT, OR = 0.68, 95%CI = 0.47-0.99, P = 0.04. This evidence concerns the gene TCF21 and breast cancer.